# 2717 Partners

2717 Partners is an Asset Manager based in San Francisco, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** San Francisco, United States
- **Region:** North America
- **Address:** New York, NY, United States
- **Founded:** 2018
- **Assets under management:** Undisclosed
- **Website:** 2717partners.com
- **LinkedIn:** https://www.linkedin.com/company/2717-partners

## Regulatory record

- **CRD number:** 329523
- **SEC file number:** 802-132063
- **Registration status:** Registered
- **Reports private funds:** Yes
- **IAPD record:** https://adviserinfo.sec.gov/firm/summary/329523

## About

Helping technology and business services businesses unlock their potential | 2717 Partners, LP engages in fundamental value‐based investing with the ability to become active in situations to create asymmetric risk/reward opportunities. The firm invests in global, small and mid cap companies operating in the software, fintech, and tech-enabled services sectors. Our longer‐term investment horizon, concentrated portfolio construction, and industry expertise enable focused due diligence and research.

## Sectors

- Healthcare Services
- Digital Health
- Pharmaceuticals

## People

- Lindsay M. A. Rosenwald — Chairman
- Fred Z. Dwek — Managing Member
- Michael S. Weiss — Managing Member

## Questions

### Who runs investment decisions at 2717 Partners?

Managing Members Fred Dwek and Michael Weiss lead day-to-day investment and operational decisions alongside Chairman Lindsay Rosenwald. Rosenwald acts as the originating force for the overall pipeline and syndicate relationships, while Dwek and Weiss handle structuring, legal execution, and portfolio company oversight. The three have worked together across multiple predecessor entities spanning more than two decades.

### What is the relationship between 2717 Partners and Fortress Biotech?

2717 Partners shares management and strategic DNA with Fortress Biotech, which Lindsay Rosenwald co-founded and where Michael Weiss served as Executive Vice Chairman and interim CEO. Both entities develop internally incubated biotech companies, though 2717 Partners operates as a distinct partnership series with its own capital base and portfolio construction approach. The crossover reflects the principals' long-standing practice of launching successive vehicles under different banners.

### How does 2717 Partners source its drug candidates?

The firm licenses molecules from academic medical centers, research hospitals, and government laboratories — past sources include the National Institutes of Health and Memorial Sloan Kettering. Rosenwald's decades-long network in oncology research provides a proprietary origination funnel that bypasses the competitive auction processes typical of larger biotech venture funds. The group then recruits specialized management teams for each company.

## Related profiles

- [Blockchain Assets Manager](https://altss.com/profile/blockchain-assets-manager)
- [Everman Prosperity](https://altss.com/profile/everman-prosperity)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/2717-partners-lp

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology